|
|
|
Immune memory typically takes up to five days to develop, so there often is not enough time for immune memory to mount a protective response[3]. At 45 days, all of the animals in the untreated group had either died or had to be sacrificed based on animal care rules. of Duke University. These results have also been used to design a proof of principle study in non-human primates, which is expected to begin within the next thirty days. This approach has the added benefit of not requiring biodosimetry (a means of laboratory analysis of the blood to determine the level of radiation exposure). Studies will shortly be initiated to further explore AEOL 10150's ability to protect the skin and lungs from damage due to exposure to mustard gas, and to protect the lungs from exposure to chlorine gas.
About Aeolus Pharmaceuticals
Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation.
2mg bar overnight xanax does xanax affect thalamus iv xanax xr mixing dramamine and xanax morphine xanax what is zoloft and xanax xanax online no prescription xanax withdrawal seizures likelyhood
Studies funded by the National Institutes for Health are currently underway evaluating AEOL 10150 as a treatment for exposure to mustard gas and will shortly be initiated to evaluate the compound as a treatment for exposure to chlorine gas. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. February 2008 update. The symptoms, which can include sudden onset of fever, rash, headache and stiff neck, can progress rapidly.
About Aeolus Pharmaceuticals
Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. In particular, management's expectations regarding Menveo could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including an unexpected inability to meet the requirements of the FDA: unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Additionally, based on its mechanism, it is believed that the compound may potentially protect against exposure to chlorine gas. “We believe AEOL 10150 could be a compelling countermeasure for Acute Radiation Syndrome (“ARS”) and are committed to working with our partners at Duke University, the University of Maryland and the National Institutes of Health (NIH) National Institutes of Allergies and Infectious Diseases (NIAID) to accelerate the development and approval of this product with the goal of providing protection against nuclear and radiological threats to the citizens of our country.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005